Hybrid Adeno-Retroviral Vector for the Transformation of Cells (E-258-1998)

The invention described and claimed in this patent application provides for novel hybrid vectors which may be used for cell transformation, either in vivo or in vitro. The hybrid vectors have an adenoviral backbone with retroviral long terminal repeats (LTRs). Such vectors are capable of transforming dividing or non-dividing cells and integrate stably into the chromosome providing a means of efficient, reliable, long-term gene expression. The vector was packaged as a recombinant adenovirus and delivered to the target cell. Unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest, and retroviral structural proteins are not required.


Changyu Zheng (NIDCR)  ➽ more inventions...

Brian O'connell (NIDCR)  ➽ more inventions...

Bruce Baum (NIDCR)  ➽ more inventions...

Intellectual Property:
PCT Pat: 7,618,623 issued 2009-11-17
US Pat: 7,052,904 issued 2006-05-30
US Application No. 11/255,059 filed on 2005-10-19
US Application No. 10/182,644 filed on 2002-07-30
US Application No. 12/488,464 filed on 2009-06-19

C Zheng et al. Genomic integration and gene expression by a modified adenoviral vector. Nature Biotechnol. 2000 Feb;18(2):176-180. [PubMed abs]
C Zheng and BJ Baum. Long-term expression after infection by the hybrid vector AdLTR-luc is from integrated transgene. Biochem Biophys Res Commun. 2002 Feb 15;291(1):34-40. [PubMed abs]
C Zheng et al. Integration efficiency of a hybrid adenoretroviral vector. Biochem Biophys Res Commun. 2003 Jan 3;300(1):115-120. [PubMed abs]
C Zheng et al. Inclusion of Moloney murine leukemia virus elements upstream of the transgene cassette in an E1-deleted adenovirus leads to an unusual genomic integration in epithelial cells. Virology. 2003 Sep 1;313(2):460-472. [PubMed abs]

Licensing Contact:
Vladimir Knezevic, M.D.
Email: vlado.knezevic@nih.gov
Phone: 301.443.5560

OTT Reference No: E-258-1998-0
Updated: Apr 1, 2004